Skip to main content
. 2021 May 24;6(10):e138027. doi: 10.1172/jci.insight.138027

Figure 9. miR-30 inhibits FGF-23–, IS-, Ang II–, and TGF-β–induced cardiomyocyte hypertrophy in vitro.

Figure 9

(A) Representative fluorescein-conjugated phalloidin staining of the NRVMs (original magnification, ×400; scale bar: 50 nm). (B–E) miR-30 reduces relative cross-sectional area of prohypertrophic stimuli-treated cardiomyocytes. **P < 0.01 compared with values indicated by the dashed line, by Kruskal-Wallis test. Dunn’s multiple comparisons test was used for multiple comparison. Data are shown as median and quartiles, as well as the minimum and maximum values of the distribution. n = 40 cells per group, in triplicated experiments. (F–I) In addition to TGF-β, miR-30 inhibits the upregulation of Anp in prohypertrophic stimuli-treated cardiomyocytes. Expression levels are normalized by 18S. *P < 0.05 and **P < 0.01 compared with values indicated by the dashed line, by 1-way ANOVA test. Tukey’s multiple comparisons test was used for multiple comparison. Data are shown as mean ± SD of at least 3 independent experiments.